In our on-going study, as suggested by the reviewing study section, we have concentrated on the examination of antitumor activity of the hormone-like peptide, tuftsin. Based on these results, we are now proposing to undertake the following studies to prepare for the future clinical study of this compound as a biological response modifier for cancer: 1. To produce a sufficient quantity fo highly purified tuftsin by the solid phase procedure and liquid chromatographies. 2. To develop a sensitive immunoassay to determine the levels of tuftsin. Monoclonal antibody will be produced against tuftsin-conjugated bovine serum albumins utilizing the hybridoma technique to establish an enzyme-lined immunosorbent assay for tuftsin. 3. To determine the most effective mode of administration of tuftsin. Three mouse systems, Ch1 B cell lymphoma, B-16 melanoma and Lewis lung carcinoma, will be utilized for this purpose. 4. To perform the toxicity study of the synthetic tuftsin using three species of animals, mouse, rabbit, and dog.
| Nishioka, K; Hopfer, R L; el-Hagin, T et al. (1986) Prophylaxis of Candida albicans infection with tuftsin. J Antimicrob Chemother 17:361-3 |
| Banks, R A; Nishioka, K; Kazazi, F et al. (1985) Effect of tuftsin on in vivo development of 3-methylcholanthrene-induced primary fibrosarcoma and Lewis lung carcinoma in mice. J Natl Cancer Inst 74:1079-83 |
| Schantz, S P; Romsdahl, M M; Babcock, G F et al. (1985) The effect of surgery on natural killer cell activity in head and neck cancer patients: in vitro reversal of a postoperatively suppressed immunosurveillance system. Laryngoscope 95:588-94 |
